This study seeks to determine the role of automated flow cytometry in detecting transitional cell carcinoma of the bladder, in monitoring its response to therapy, and in determining the malignant potential of individual tumors. Efforts will be directed toward: 1. Improving sample preparation, staining and storage of bladder washing and urine specimens. (This will include exploring protocols for fixation and staining as well as nuclear isolation.) 2. Using paraffin-embedded pathology specimens in retrospective studies for bladder cancer patients whose clinical outcome is known. (This will include evaluating DNA histograms for DNA index, percent cycling cells, statistical spread including SD and CV, and comparing the histogram parameters to the known clinical course of the disease. In addition, several choices of second parameters will be explored to enhance diagnostic accuracy. These will include the use of antibodies (both polyclonal and monoclonal) directed against oncogene products as well as monoclonal antibodies raised against bladder cancer cells.) 3. Using freshly obtained bladder tissue for ongoing DNA flow cytometry studies comparing the histogram parameters mentioned above to the clinical course and pathological grade and stage of the tumor. 4. Studies of oncogene expression as determined by levels of specific oncogene-derived products to use in (1) semiquantitative immunoperoxidase assays and (2) the two-parameter studies described above. 5. Developing improved histogram analysis protocols and establishing an appropriate data base for correlating the data obtained to the clinical course of the disease in order to determine which of the parameters studied, including clinical and pathological descriptions, are predictive of single tumor occurrence of recurrent tumors of the same stage, or tumor progression. Furthermore, we will attempt to decide which of these parameters best predicts which lesions will be responsive to chemotherapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA041034-03
Application #
3548788
Study Section
(SRC)
Project Start
1985-09-29
Project End
1989-09-30
Budget Start
1987-09-01
Budget End
1989-09-30
Support Year
3
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Deitch, A D; Andreotti, V A; Strand, M A et al. (1990) A clinically applicable method to preserve urine and bladder washing cells for flow cytometric monitoring of bladder cancer patients. J Urol 143:700-5
Deitch, A D; Anderson, K A; deVere White, R W (1990) Evaluation of DNA flow cytometry as a screening test for bladder cancer. J Occup Med 32:898-903
Baker, W C; deVere White, R; Rossitto, P V et al. (1988) Quantitative analysis of keratin 18 in the urine of patients with bladder cancer. J Urol 140:436-9
deVere White, R W; Deitch, A D; West, B et al. (1988) The predictive value of flow cytometric information in the clinical management of stage O (Ta) bladder cancer. J Urol 139:279-82
Rossitto, P V; Chan, R; Strand, M A et al. (1988) Characterization of urinary keratin number 18 using a new assay. J Urol 140:431-5
deVere White, R W; Deitch, A D; Baker Jr, W C et al. (1988) Urine: a suitable sample for deoxyribonucleic acid flow cytometry studies in patients with bladder cancer. J Urol 139:926-8